La chaîne d'options affiche les données clés des options sur actions de BioVie à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour BioVie..

BioVie (NASDAQ:BIVI) Stock, Chaîne d'Options

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

BioVie Inc

BIVICTRIX THERAPEUTICS PL by BIVICTRIX THERAPEUTICS PLC

Health Care

Press Releases

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

News

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

Management

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

IPOs

BioVie Inc. Announces Pricing of $12 Million Public Offering

Financing

BioVie Inc. Announces Closing of $12 Million Public Offering

General

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

BIVI

Aditxt

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

GRI Bio

Liminatus Pharma

Oragenics

Onconetix

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Longevity Health Holdings, Inc. - Common Stock

Comments

BioVie

BioVie (BIVI) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL